Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:31:23 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
Next:Defending champion South Carolina to open season in Las Vegas against Michigan
You may also like
- With Djokovic awaiting the winner, Murray trails Hanfmann at rain
- Boca Raton's most expensive waterfront property sold for $40M
- The foods that cancer experts want you to stop eating
- Woman, 62, is left baffled as she turns up to a hospital scan only to be told she's already dead
- Sports betting roundup: Xander Schauffele's final putt pays off for bettors
- Hospital operator Steward Health Care files for bankruptcy protection
- Stars and DeBoer moving on after ousting Cup champ Vegas in tight 7
- Milwaukee election leader ousted 6 months before election in presidential swing state
- The 13 style rules that every midlife woman MUST follow (and yes, beige really is banned!)